Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- EXAI
- Price
- 4.84
- Stock movement up
- +0.13 (2.76%)
- Company name
- Exscientia Ltd ADR
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 633.18M
- Ent value
- 671.38M
- Price/Sales
- 31.77
- Price/Book
- 2.48
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -16.84%
- 3 year return
- -38.95%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-09
DIVIDENDS
EXAI does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 31.77 |
| Price to Book | 2.48 |
| EV to Sales | 33.69 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 130.82M |
| EPS (TTM) | -1.00 |
| FCF per share (TTM) | -0.91 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 19.93M |
| Gross profit (TTM) | -10.17M |
| Operating income (TTM) | -148.86M |
| Net income (TTM) | -130.39M |
| EPS (TTM) | -1.00 |
| EPS (1y forward) | -0.57 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -51.05% |
| Operating margin (TTM) | -746.96% |
| Profit margin (TTM) | -654.25% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 117.79M |
| Net receivables | 49.62M |
| Total current assets | 299.16M |
| Goodwill | 5.95M |
| Intangible assets | 46.68M |
| Property, plant and equipment | 0.00 |
| Total assets | 411.41M |
| Accounts payable | 7.47M |
| Short/Current long term debt | 18.57M |
| Total current liabilities | 65.94M |
| Total liabilities | 155.99M |
| Shareholder's equity | 255.42M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -134.71M |
| Capital expenditures (TTM) | 16.16M |
| Free cash flow (TTM) | -118.53M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -51.05% |
| Return on Assets | -31.69% |
| Return on Invested Capital | -50.42% |
| Cash Return on Invested Capital | -45.84% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.84 |
| Daily high | 4.84 |
| Daily low | 4.84 |
| Daily Volume | 0K |
| All-time high | 25.26 |
| 1y analyst estimate | 4.35 |
| Beta | 0.83 |
| EPS (TTM) | -1.00 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 19 May 2025 |
Downside potential
Loading...
Downside potential data
| EXAI | S&P500 | |
| Current price drop from All-time high | -80.84% | -1.38% |
| Highest price drop | -84.20% | -56.47% |
| Date of highest drop | 25 Apr 2024 | 9 Mar 2009 |
| Avg drop from high | -65.21% | -11.07% |
| Avg time to new high | 790 days | 12 days |
| Max time to new high | 789 days | 1805 days |
COMPANY DETAILS
Marketcap
633.18M
Marketcap category
Small-cap
Description
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité " Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Employees
483
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner